Alva10

Focused in driving up value for diagnostics in Precision Medicine

[Alva10 @DxforPM]

Our CEO @Hannah_Mamuszka explores the newly approved #Alzheimer’s drug #Aduhelm; the challenges with new, expensive drugs of dubious benefit; and the importance of understanding how an Alzheimer’s diagnosis was reached before a patient agrees to try "trial and error" medicine.

[Pioneer Institute @PioneerBoston]

Alzheimer Breakthrough Disillusionment: Confusion on FDA’s Approval of Expensive and Possibly Ineffective Drug via Pioneer Institute https://t.co/j5KJWy9OY8

[Alva10 @DxforPM]

How do we treat a disease we can't even diagnose? Our CEO @Hannah_Mamuszka shares her perspective on @biogen's approval in #alzheimers and why Alzheimer's disease makes the case for #diagnostics! https://t.co/4dUXiRUgyI
#precisionmedicine #aduhelm #alzheimersdisease

[Alva10 @DxforPM]

Our founder @Hannah_Mamuszka has worked on the laboratory and business sides of #healthcare, in both #pharma and #diagnostics, to shift thinking about the payer-employer-diagnostic industry relationship. Learn about Hannah and Alva10. https://t.co/OsTDMJmPhD #DXforPM

[Alva10 @DxforPM]

Our co-founder @lena_chaihorsky understands the importance of value-based reimbursement strategies, so she is working to create an economic ecosystem for #dx companies to improve health outcomes and payer economics. Learn about Lena and Alva10 - https://t.co/OsTDMJmPhD #DXforPM

[Alva10 @DxforPM]

When detected early, the #breastcancer 5-year relative survival rate is 99%. Talk to your physician about genetic testing & #diagnostic screening for mutations to assess your lifetime risk so they can closely observe for the earliest signs of cancer. #NWHW https://t.co/iDmAtVPsZc

[Alva10 @DxforPM]

Improved access to non-invasive #diagnostics can allow women to get checked easily and diagnosed for a range of health issues, and empower their physicians with the information to create optimized treatment plans that support the best patient outcomes. #NWHW #WomensHealthWeek

[President Biden Archived @POTUS46Archive]

COVID-19 has shown us just how necessary it is to center the needs of women and girls in our health care system. This National Women's Health Week, we’re doubling down on our commitment to equal access to health care. https://t.co/r5ETZ5UwDJ

[Alva10 @DxforPM]

The pandemic underscored the importance of diagnostics; use #NationalWomensCheckupDay to schedule an annual exam & ask your physician how #diagnostics can be leveraged to identify disease risk & optimal treatment strategies based on your genomics https://t.co/FrJdV6DQ6i #NWHW

[Alva10 @DxforPM]

Specialty drugs accounted for 52% of pharmacy spend in 2020. By moving #diagnostics to the forefront of #PrecisionMedicine, we can #EndTrialandErrorMedicine & enable more effective treatments, better health outcomes, & reduced healthcare spending. https://t.co/5Vve9uffqT #DXforPM

[Alva10 @DxforPM]

Our CEO @Hannah_Mamuszka looks at the lack of #diagnostics for #alzheimers and #nash, and how the US healthcare system must change to encourage innovation and foster progress for diagnosing and treating these diseases more effectively in the future. https://t.co/zsVGrr54cb

[Alva10 @DxforPM]

Trodelvy received accelerated approval, w/ just a 5.4% complete & 22.3% partial response rate for metastatic urothelial cancer, & side effects warranting a boxed warning. #Diagnostics could identify efficacy for patients - https://t.co/RYNBf6nOoi. #EndTrialandErrorMedicine

[Alva10 @DxforPM]

The status quo in #healthcare isn’t working and we’ve made it our mission to change it. Find out how we unleash the knowledge gap between #payers and #diagnostic companies for optimized patient outcomes and payer economics. https://t.co/CFC5AwU6UP #DXforPM

[Alva10 @DxforPM]

The #FDA panel voted in favor of maintaining 4 of 6 accelerated approvals despite negative findings in confirmatory trials. Questionable efficacy underscores the importance of #diagnostics to enable patients to get the right treatments based on genetics. https://t.co/XujCjbGy5A

[Alva10 @DxforPM]

Advancements in #diagnostics are improving the chance for early, accurate detection of many diseases. Everyone deserves access to advanced diagnostics and personalized health treatments. #MinorityHealthMonth

[Alva10 @DxforPM]

The #FDA Advisory Committee favors #Tecentriq maintaining accelerated approval for PD-L1-Positive, Metastatic Triple-Negative #BreastCancer. #Diagnostics should be used to identify patients who will/won't respond to it, but that is not currently required. https://t.co/uwd8bXdLtl

[Alva10 @DxforPM]

In trials, #zynlonta has a 24% complete response rate & 24.3% partial response rate for adults with diffuse large B-cell #lymphoma. For patients with #DLBCL, #diagnostics could identify whether this drug will be effective. https://t.co/ibioZPUvHZ #EndTrialandErrorMedicine

[Alva10 @DxforPM]

From @NEJM: #FDA's reevaluation of accelerated approvals for 35 oncology indications for anti–programmed death ligand 1 antibodies revealed 10 indications did not end up confirming benefit and yet their marketing authorization continued. https://t.co/d0WUHqHsaG

[Alva10 @DxforPM]

As we debate if these drugs show overall benefit, a small set of patients did have a chance at longer survival. Introducing #diagnostics in the approval process can instill more confidence in #FDA's accelerated pathway & identify patients likely to respond https://t.co/Ofr4WzETPZ

[Alva10 @DxforPM]

We hope this week’s Oncologic Drugs Advisory Committee meeting will result in more meaningful use of biomarkers & companion #diagnostics in the #drugapproval process. But employers also have a big role to play in advocating for #precisionmedicine! https://t.co/BAHHPEz42L

[Alva10 @DxforPM]

10 indications of #oncology drugs granted accelerated FDA approval have been called into question; many more have yet to be resolved. We hope greater use of #diagnostics will be considered at the #Oncologic Drugs Advisory Committee meeting this week. https://t.co/NbGJpq6Yrq

[Alva10 @DxforPM]

@cancer_womb Absolutely! But for those unlikely to respond to a drug, it would be best to know up front via diagnostic testing so they can find a better-suited option and not lose precious time and financial resources on a trial-and-error treatment path that won’t be effective for them.

[Alva10 @DxforPM]

In trials to date, #dostarlimab only has a 12.7% complete response rate & 29.6% partial response rate. For patients with #endometrialcancer, access to #diagnostics could identify whether this drug will be effective for them to take the trial-and-error out of their treatment.

[Oncology Nursing News @OncNursingNews]

BREAKING: The @US_FDA has approved dostarlimab (Jemperli) for the treatment of certain patients with recurrent or advanced endometrial cancer. https://t.co/OrGndb3svw